$245.6 M

ONCR Mkt cap, 23-Sept-2021
Oncorus Net income (FY, 2020)-48.3 M
Oncorus EBIT (FY, 2020)-37.2 M
Oncorus Cash, 31-Dec-2020130.3 M
Oncorus EV158 M
Get notified regarding key financial metrics and revenue changes at OncorusLearn more
Banner background

Oncorus Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

R&D expense

12.5m24.0m27.2m

General and administrative expense

6.0m7.1m10.0m

Operating expense total

18.6m31.2m37.2m

EBIT

(18.6m)(31.2m)(37.2m)

Interest income

228.0k509.0k143.0k

Income tax expense

Net Income

(18.0m)(30.7m)(48.3m)

EPS

(22.9)(37.4)

Half Year

USDH1, 2019H1, 2020

R&D expense

12.0m12.6m

General and administrative expense

2.5m4.1m

Operating expense total

14.4m16.7m

EBIT

(14.4m)(16.7m)

Interest income

167.0k136.0k

Net Income

(14.3m)(17.2m)

EPS

(15.8)(22.7)

Oncorus Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

20.1m45.3m130.3m

Prepaid Expenses

3.1m

Current Assets

20.9m45.9m133.4m

PP&E

4.3m4.5m4.2m

Total Assets

25.7m50.8m182.3m

Accounts Payable

975.0k942.0k1.2m

Short-term debt

993.0k

Current Liabilities

2.7m4.9m6.0m

Long-term debt

41.6m

Total Debt

42.6m

Total Liabilities

4.8m8.5m47.6m

Common Stock

2.0k

Preferred Stock

60.9m116.6m

Additional Paid-in Capital

906.0k264.5m

Retained Earnings

(41.0m)(74.3m)(129.8m)

Total Equity

(40.1m)(74.3m)134.7m

Financial Leverage

-0.6 x-0.7 x1.4 x

Quarterly

USDQ2, 2020

Cash

28.9m

Current Assets

30.6m

PP&E

4.8m

Total Assets

35.8m

Accounts Payable

1.9m

Current Liabilities

6.1m

Total Liabilities

10.1m

Preferred Stock

122.1m

Retained Earnings

(96.3m)

Total Equity

(96.3m)

Financial Leverage

-0.4 x

Oncorus Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(18.0m)(30.7m)(48.3m)

Depreciation and Amortization

956.0k1.1m1.4m

Accounts Payable

284.0k

Cash From Operating Activities

(17.2m)(27.2m)(36.8m)

Purchases of PP&E

(291.0k)(977.0k)(1.1m)

Cash From Investing Activities

(291.0k)(977.0k)(1.1m)

Cash From Financing Activities

24.5m53.4m125.8m

Net Change in Cash

7.0m25.2m87.9m

Quarterly

USDQ2, 2019Q2, 2020

Net Income

(14.3m)(17.2k)

Depreciation and Amortization

519.0k628.0k

Cash From Operating Activities

(11.0m)(15.6m)

Purchases of PP&E

(118.0k)(747.0k)

Cash From Investing Activities

(118.0k)(747.0k)

Cash From Financing Activities

28.0k5.0k

Net Change in Cash

(11.1m)(16.4m)

Oncorus Ratios

USDFY, 2018

Financial Leverage

-0.6 x

Oncorus Operating Metrics

Q2, 2020

Research Stage Products

3

Phase I Trials Products

1

Patents (US)

15

Patents (Foreign)

11

Patent Applications (US)

15

Patent Applications (Foreign)

106

Oncorus Employee Rating

4.15 votes
Culture & Values
5
Work/Life Balance
5
Senior Management
5
Salary & Benefits
4
Career Opportunities
3
Source